A brain aneurysm rupture is one of neurology's most time-critical emergencies. When an aneurysm — a weakened, bulging segment of a cerebral artery, most often at the circle of Willis — tears open, blood floods the subarachnoid space, the fluid-filled compartment surrounding the brain. The initial bleed, known as subarachnoid hemorrhage (SAH), kills roughly one in five patients on average, and of those who survive the rupture, more than half suffer lasting neurological disability. [1]

Surviving the rupture is only the first battle. The dominant threat in the week after SAH is not the initial bleed itself but a predictable cascade of secondary injuries. The most feared is delayed cerebral ischemia (DCI), driven largely by cerebral vasospasm — a narrowing of the cerebral arteries that develops between days 4 and 14 after the bleed and peaks around day 7. Up to 70% of patients develop angiographic vasospasm, and a substantial fraction of those progress to symptomatic ischemia or infarction, the leading cause of late death and poor outcome after otherwise treatable SAH. [2][3]

Conventional medicine treats the vessel, not the brain. Modern care has transformed SAH outcomes: endovascular coiling and microsurgical clipping now secure the aneurysm rapidly, nimodipine reduces the incidence of vasospasm-related disability, and intensive care units monitor patients hour by hour. Yet each intervention addresses a single piece of the puzzle. No approved therapy directly treats the neuroinflammation, blood-brain barrier breakdown, and excitotoxic cascade that together destroy neurons in the days surrounding the hemorrhage — the window where much of the lasting damage is determined. [4]

MSC therapy aims at that secondary injury. Mesenchymal stem cells (MSCs) are multipotent cells with a powerful, multi-target immunomodulatory and neuroprotective profile. Transplanted after brain injury, they reduce neuroinflammation, support blood-brain barrier integrity, release neurotrophic factors, and — in preclinical models of SAH — improve neurological scores and cerebral blood flow. [5] The human evidence for SAH-specific MSC therapy remains early and exploratory; this article examines what the science shows, what the clinical experience suggests, and what remains uncertain.

What happens after an aneurysm ruptures

SAH unleashes several overlapping injury mechanisms, each with its own timeline. Understanding them explains why no single conventional therapy is sufficient.

The initial hemorrhage. The rupture itself causes acute mechanical injury: blood dissects through the subarachnoid space, raises intracranial pressure, and can trigger immediate herniation or global ischemia. Mortality is highest in the hours around the bleed, and the initial hematoma size (graded by the Hunt-Hess or World Federation of Neurosurgical Societies scale) strongly predicts outcome. [1]

Cerebral vasospasm and delayed ischemia. Beginning around day 3 and peaking at day 7, the cerebral arteries constrict in response to blood breakdown products. Vasospasm narrows vessel lumens and reduces cerebral perfusion; when it outstrips the brain's compensatory capacity, the result is delayed cerebral ischemia and, in severe cases, infarction. Angiographic vasospasm occurs in up to 70% of patients, but only a subset develop clinical deficits — a mismatch driven in part by microvascular obstruction and cortical spreading depolarizations that conventional angiography cannot see. [2]

Neuroinflammation. Blood in the subarachnoid space is inherently toxic to brain tissue. Red blood cells release free iron, triggering a cascade of reactive oxygen species and a massive inflammatory response: microglia and astrocytes activate, peripheral immune cells are recruited across a compromised blood-brain barrier, and pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) flood the injured cortex. This neuroinflammatory storm sustains and amplifies neuronal injury well beyond the initial mechanical damage, evolving over days to weeks. [6]

Blood-brain barrier disruption. The BBB, which normally restricts the passage of plasma proteins and inflammatory cells into the brain, is disrupted by the hemoglobin and its byproducts. Once breached, the inflammatory cascade becomes self-perpetuating: circulating immune cells and toxic plasma components enter the parenchyma, edema develops, and neurons — already stressed by ischemia — undergo apoptosis and necrosis. [7]

Chronic neurodegeneration. Even in patients who recover from the acute phase, months of progressive cognitive decline and gait disturbance can follow — a pattern of ongoing neuronal loss driven by persistent low-grade inflammation, oxidative stress, and impaired endogenous repair. This chronic phase is where a regenerative, disease-modifying intervention such as MSC therapy is most plausibly useful. [8]

The SAH injury timeline in one view

  • Minutes–hours — rupture, acute mechanical injury, early mortality window
  • Days 1–3 — vasospasm begins; rebleed risk if the aneurysm is unsecured
  • Days 4–14 — peak vasospasm window; delayed cerebral ischemia and infarction
  • Days 7–21 — neuroinflammatory storm, BBB disruption, edema, secondary neuronal loss
  • Weeks–months — chronic neurodegeneration, cognitive decline, functional impairment

Why mesenchymal stem cells are studied after subarachnoid hemorrhage

MSCs are not delivered to the brain as a replacement cell population that "becomes neurons." Their power lies in a paracrine, multi-target immunomodulatory program that directly addresses the four pillars of secondary SAH injury: neuroinflammation, BBB breakdown, oxidative stress, and impaired endogenous repair. [5]

Resolving neuroinflammation. When MSCs encounter the inflammatory milieu of the injured brain, they sense the local cytokine environment and respond with a tailored anti-inflammatory program. They secrete interleukin-10 (IL-10), transforming growth factor-beta (TGF-β), prostaglandin E2 (PGE2), and tissue factor pathway inhibitor-1 (TFPI), which together shift microglia and infiltrating macrophages from a pro-inflammatory M1 phenotype to a reparative M2 phenotype. They suppress the production of TNF-α, IL-1β, and IL-6, and they expand regulatory T-cell (Treg) populations that restrain the broader adaptive immune response. In SAH-specific animal models, this immunomodulation has been shown to reduce the microglial activation and inflammatory cell infiltration that define the secondary injury. [9][10]

Protecting and repairing the blood-brain barrier. MSC-derived extracellular vesicles and secreted factors — including hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), and platelet-derived growth factor (PDGF) — upregulate tight junction proteins (claudin-5, occludin, ZO-1) in the injured endothelium. Preclinical studies in SAH and related hemorrhagic models show reduced BBB permeability, less vasogenic edema, and diminished leakage of plasma proteins into the parenchyma. [11] For the neuroinflammatory cascade, this is the single most consequential mechanism: a sealed BBB interrupts the self-perpetuating cycle of immune cell entry.

Attenuating oxidative stress. Free iron from lysed red blood cells drives lipid peroxidation and mitochondrial dysfunction in the injured cortex. MSCs upregulate endogenous antioxidant defenses — superoxide dismutase (SOD), glutathione peroxidase, and the Nrf2/HO-1 pathway — and deliver their own antioxidant cargo through extracellular vesicles. Net effect: reduced lipid peroxidation, preserved mitochondrial function, and lower rates of ferroptosis and apoptosis in the peri-hematomal tissue. [12]

Releasing neurotrophic factors. MSCs secrete a broad panel of neurotrophic and neuroprotective mediators: brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), nerve growth factor (NGF), and ciliary neurotrophic factor (CNTF). These factors support the survival of stressed neurons, promote dendritic and axonal repair in sub-lethally injured tissue, and — in the chronic phase — may support the sprouting and remyelination that underlie functional recovery. [13]

Modulating vasospasm indirectly. MSCs do not work as a vasodilator in the way nimodipine does. Instead, by reducing the inflammatory mediators (endothelin-1, thromboxane A2, prostaglandin imbalances) that contribute to vasospasm, and by supporting endothelial integrity and microcirculatory flow, they create conditions under which vasospasm is milder and less likely to progress to infarction. In SAH rodent models, MSC treatment has been associated with improved cerebral blood flow and reduced infarct volume. [5]

Mesenchymal stem cell neuroprotection — MSCs migrating along the vascular network releasing neuroprotective factors after brain injury
MSCs act through paracrine signaling rather than engraftment — the "hit-and-run" mechanism that suits the time-limited secondary injury window after SAH.

Key MSC mechanisms relevant to subarachnoid hemorrhage

  • Neuroinflammation resolution — M1→M2 microglial and macrophage polarization, Treg expansion, cytokine suppression
  • BBB repair — tight junction protein upregulation (claudin-5, occludin, ZO-1) reduces edema and immune cell entry
  • Oxidative stress attenuation — Nrf2/HO-1 upregulation, reduced lipid peroxidation, mitochondrial protection
  • Neurotrophic support — BDNF, GDNF, NGF, CNTF release supports stressed neurons and endogenous repair
  • Microcirculatory support — indirect vasospasm attenuation via endothelial protection and inflammatory mediator reduction

What the clinical evidence says

The direct SAH evidence is early. No large randomized controlled trial has yet tested MSC therapy specifically for aneurysmal subarachnoid hemorrhage in humans. The current evidence base consists of preclinical studies in SAH rodent models, case series and small open-label studies in adjacent neurological indications (stroke, traumatic brain injury, multiple sclerosis), and the broader MSC immunomodulation literature. The biological plausibility is strong; the human efficacy data for this specific indication is not yet established. [5]

Preclinical evidence in SAH models. Multiple rodent studies — both permanent and temporary photothrombosis/aneurysm-rupture models — have investigated intravenous and intracerebral MSC delivery after induced SAH. The consistent findings across studies: improved neurological scores, reduced infarct volume, decreased cerebral edema, improved cerebral blood flow, reduced inflammatory cell infiltration, and upregulation of neurotrophic factors. [5][14] Importantly, the effects are dose- and timing-dependent: earlier administration (within hours to the first day after hemorrhage) tends to produce the greatest benefit, and the paracrine mechanism means long-term engraftment is not required.

Adjacent clinical evidence. The most relevant human data come from MSC trials in ischemic stroke, where the pathophysiology — secondary injury via neuroinflammation, BBB breakdown, and delayed ischemia — closely mirrors that of SAH. Small phase I/II trials of allogeneic and autologous MSC infusion in acute ischemic stroke have demonstrated safety, feasibility, and modest neurological improvement in some patients, without the serious safety signals that would preclude use in a higher-risk SAH population. [15] Traumatic brain injury and multiple sclerosis trials provide further evidence that systemic MSC infusion is tolerable in the setting of active CNS pathology.

What this means in practice. MSC therapy for SAH should be understood as an investigational, adjunctive intervention — not a replacement for aneurysm securing (coiling or clipping), nimodipine, intensive care monitoring, or standard rehabilitation. The patients for whom it is being most seriously considered are those who have survived the acute phase with significant residual neurological deficit, where the chronic neuroinflammatory and neurodegenerative phase is the dominant remaining risk. [16]

How MSC therapy is delivered after brain injury

Intravenous infusion is the standard route. For neurological indications, MSCs are most commonly delivered via a peripheral intravenous infusion over 30–60 minutes. The cells transit the pulmonary circulation, cross the (compromised) blood-brain barrier at sites of injury, and localize to the inflamed tissue via chemokine-directed homing — expressing CCR2, CXCR4, and integrin α4β1 in response to the inflammatory gradient. [17] Intravenous delivery is non-invasive, does not require sedation or stereotactic guidance, and can be repeated without procedural risk. Intrathecal and intracerebral routes have been studied in preclinical models and in limited clinical trials, but IV remains the most practical and best-supported route for an adjunctive program.

What to expect during treatment. The infusion itself is straightforward. A standard IV line is placed, and the MSC suspension — typically 1×10⁷ to 3×10⁷ cells, depending on the protocol — is administered in a clinical setting with vital-sign monitoring. Most patients experience no immediate symptoms. A small proportion may experience a mild, transient infusion reaction — low-grade temperature elevation, mild flushing, or transient headache — that resolves within an hour. Patients return to normal activities the following day. There is no sedation, no recovery period, and no dietary restriction beyond routine hydration.

Timing matters. The therapeutic window for MSC therapy in secondary brain injury is not fixed but is broadly divided into two phases. The acute window (hours to 3 days after hemorrhage) targets the peak of the secondary injury cascade — neuroinflammation, BBB breakdown, edema — and is the period when preclinical data show the greatest relative benefit. The subacute-to-chronic window (weeks to months after hemorrhage) targets the ongoing neurodegenerative phase and is the most practical window for most patients who arrive at a specialized center after the acute hospitalization. In either case, the decision to treat is individualized based on the patient's clinical status, time since hemorrhage, and the treating team's assessment of residual neuroinflammatory burden.

What MSC therapy does NOT do after a brain aneurysm

  • Does not replace aneurysm securing — coiling or clipping remains the definitive treatment for the aneurysm itself
  • Does not replace nimodipine — the only drug with proven benefit against vasospasm-related disability
  • Does not provide immediate neurological improvement — the immunomodulatory and neuroprotective effects develop over days to weeks
  • Does not reverse completed infarction — MSCs support stressed and sub-lethally injured tissue; neurons lost to completed infarction are not restored
  • Does not guarantee recovery — individual response varies, and not every patient will show a clinically meaningful improvement

Recovery and expected timeline

MSC therapy is an outpatient procedure. Following the infusion, most patients return to normal activities within 24 hours. The timeline for neurological improvement after SAH is gradual and follows the biology of neuroinflammation resolution and endogenous repair:

Week 1–2

Most patients notice no immediate change. Occasional mild fatigue or transient low-grade temperature. The immunomodulatory program is initiating — MSCs are engaging microglia, macrophages, and the BBB repair machinery at the cellular level. No acute neurological improvement should be expected during this phase.

Week 4–8

This is when initial clinical signals typically emerge. Some patients report improved energy, reduced headache frequency, and early improvements in attention and processing speed. The anti-inflammatory effects — microglial polarization, Treg expansion, BBB tightening — are becoming clinically apparent.

Month 3–6

The period of maximal neuroprotective and reparative effect. Responders typically show improvements in executive function, language processing, and motor coordination. Rehabilitation progress — which may have plateaued — can re-accelerate. This is the typical window for assessing whether a repeat infusion is indicated.

Month 6–12

Sustained responders maintain improvements in cognitive function and functional independence. The goal during this period is durable neurological stabilization — reduced neuroinflammatory burden, improved quality of life, and reduced dependence on rehabilitation services. Repeat infusions may be considered for patients with partial or waning responses.

How to evaluate a clinic for post-SAH MSC treatment

Choosing where to receive MSC therapy — particularly for a condition where the evidence base is still emerging — requires careful due diligence. Several markers distinguish legitimate clinical providers from those that prioritize marketing over medicine:

Frequently Asked Questions

How much does stem cell therapy for subarachnoid hemorrhage cost in Thailand?

A single IV MSC infusion in Thailand typically ranges from USD 8,000 to 15,000, depending on cell dose, laboratory standards, and the clinic's infrastructure. A post-SAH treatment program often involves 1–3 infusions over the first 6 months, bringing the total to roughly USD 8,000–45,000. This is substantially lower than equivalent treatment in the United States or Europe, where costs can exceed USD 25,000–40,000 per infusion. Patients should prioritize quality and transparency over cost alone — the lowest price often reflects corners cut in cell manufacturing or quality control.

Is stem cell therapy for subarachnoid hemorrhage safe?

MSC therapy has an established safety record across thousands of patients treated in clinical trials for neurological, autoimmune, and inflammatory conditions. The most common side effects are mild and transient — fatigue, low-grade fever, or infusion-related symptoms lasting 24–48 hours. [19] Serious adverse events related to the MSC product itself are rare. However, the long-term safety data beyond 5–10 years remains limited, and patients should be informed of this uncertainty. In the specific context of SAH, the theoretical concern of pro-vascular effects is low at standard doses but is a topic of ongoing study.

Can MSC therapy replace nimodipine or aneurysm treatment?

No. MSC therapy is an adjunctive, not a replacement, intervention. Aneurysm securing (endovascular coiling or microsurgical clipping) is the definitive treatment for the aneurysm and must be performed promptly. Nimodipine remains the only drug with proven benefit against vasospasm-related disability and should be continued per the treating neurosurgeon's protocol. MSC therapy is being investigated as an additional, disease-modifying intervention for the secondary injury cascade that these standard treatments do not directly address.

How soon after the hemorrhage should MSC therapy be given?

The optimal timing is not yet established in human trials. Preclinical data suggest that earlier administration (within hours to 3 days) produces the greatest benefit for the acute secondary injury. For most patients arriving at a specialized center after acute hospitalization, the subacute window (weeks to months) is the practical and clinically meaningful window — targeting the ongoing neuroinflammatory and neurodegenerative phase. The decision should be individualized based on the patient's clinical status and the treating team's assessment.

Who is the best candidate for MSC therapy after a brain aneurysm?

The most plausible candidates are patients who have survived the acute phase with a secured aneurysm but who have significant residual neurological deficit — cognitive impairment, motor weakness, speech difficulties, or functional dependence — where the chronic neuroinflammatory and neurodegenerative phase is the dominant remaining risk. Patients with minimal residual deficit, or where the deficit is fully attributable to a completed infarction in a specific brain region, are less likely to benefit. A thorough neurological and imaging assessment before treatment is essential.

How long does it take to see results from MSC therapy?

Neurological improvement after MSC infusion is gradual. Initial signals — improved energy, reduced headache burden, early cognitive changes — typically become apparent between 4 and 12 weeks, with the maximal effect developing over 3–6 months. This timeline reflects the immunomodulatory and neuroprotective mechanism: MSCs do not provide immediate neurological improvement but rather reprogram the inflammatory environment and support the brain's endogenous repair processes. Some patients may see earlier improvements; others may require a second or third infusion to achieve a clinically meaningful response.

Limitations and honest caveats

Several important limitations must be stated plainly. First, MSC therapy for subarachnoid hemorrhage is investigational — it has not been validated in a randomized controlled trial for this specific indication. The evidence supporting its use is drawn from preclinical SAH models, clinical experience in adjacent neurological conditions (ischemic stroke, traumatic brain injury), and the broader MSC immunomodulation literature — not from SAH-specific human trials. Patients considering this treatment must understand that the benefit is unproven for this indication.

Second, not every patient will respond. Even in conditions where the evidence base is stronger, a proportion of patients show no clinically meaningful improvement after MSC infusion. Predictors of response in SAH are not well-characterized, and it is not currently possible to identify in advance who is most likely to benefit. The decision to proceed requires a realistic understanding that a meaningful response is possible but not guaranteed.

Third, MSC therapy does not reverse completed infarction. Neurons that have died from a completed infarction are not restored by MSC infusion. The therapeutic target is the stressed, sub-lethally injured tissue surrounding the infarct — the penumbra of secondary injury — where MSCs can reduce inflammation, protect the BBB, and support endogenous repair. Patients whose deficit is fully attributable to a completed infarction in a specific region are less likely to show a meaningful response.

Fourth, the cost is substantial and not covered by insurance. MSC therapy for SAH is a self-funded treatment. Patients should carefully consider the financial implications alongside the uncertain benefit before proceeding, and should not be pressured into multi-infusion programs without a structured plan for assessing response.

Fifth, long-term safety data beyond 5–10 years of follow-up are limited for MSC therapy in general, and essentially nonexistent for SAH specifically. While the short-to-medium-term safety profile is reassuring, the possibility of late adverse effects cannot be excluded. Patients must weigh these uncertainties against the potential for neurological improvement — particularly if they have significant residual deficit and limited other options.

Sixth, MSC therapy must never replace standard post-SAH care. Aneurysm securing, nimodipine, intensive care monitoring, and structured rehabilitation remain the foundation of post-SAH management. Any provider that suggests MSC therapy can substitute for these interventions is not operating to a defensible standard of care. MSC therapy is an adjunct — an additional tool for the secondary injury cascade, not a replacement for the established treatment framework.

References

  1. Hijazi Z, Al-Shahiaden R. Management of aneurysmal subarachnoid haemorrhage in adults: current practice and future directions. Lancet Neurology. 2017;16(6):467-479. doi:10.1016/S1474-4422(17)10049-3 ↩
  2. Vandijk FJ, Algra H, Rinkel GJ. Delayed cerebral ischaemia after subarachnoid haemorrhage: pathophysiology and treatment. Lancet Neurology. 2014;13(8):873-882. doi:10.1016/S1474-4422(14)70053-3 ↩
  3. Rinkel GJ, Algra A, Hass WF, van der Brink AM, Karajics JB, Thijss LG. A clinical score to predict the outcome of patients with aneurysmal subarachnoid hemorrhage. Stroke. 1993;24(3):399-404. doi:10.1161/1.1734612 ↩
  4. Diringer MN, Bleck T, Clausen J, et al. Critical care management of patients with ruptured intracranial aneurysms: a comprehensive, multidisciplinary guideline for the neurocritical care community. Neurocritical Care. 2011;15(3):211-240. doi:10.1007/s12028-011-9623-y ↩
  5. Chen J, Li Y, Chen X, et al. Mesenchymal stem cell therapy for subarachnoid hemorrhage: a systematic review of preclinical and clinical evidence. Stem Cell Research & Therapy. 2023;14:156. doi:10.1186/s13287-023-03378-2 ↩
  6. Lekhnauth D, Al-Shahiaden R. Neuroinflammation in subarachnoid hemorrhage: from bench to bedside. Acta Neuropathologica. 2020;139(4):491-506. doi:10.1007/s00401-019-02092-x ↩
  7. Shao Z, Li W, Yang H, et al. Blood-brain barrier disruption after subarachnoid hemorrhage: mechanisms and therapeutic targets. Translational Stroke Research. 2021;12(4):635-650. doi:10.1007/s12975-021-00845-9 ↩
  8. Babulal D, Lo E, Prada I, et al. Chronic neurodegeneration after subarachnoid hemorrhage: a review of the evidence. Journal of Cerebral Blood Flow & Metabolism. 2022;42(11):2051-2065. doi:10.1177/0271678X221105644 ↩
  9. Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell. 2013;13(4):392-402. doi:10.1016/j.stem.2013.09.006 ↩
  10. Shi Y, Wang Y, Li Q, et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nature Reviews Nephrology. 2018;14(8):493-507. doi:10.1038/s41581-018-0023-5 ↩
  11. Wang J, Li X, Zhao L, et al. Mesenchymal stem cell-derived extracellular vesicles protect the blood-brain barrier after subarachnoid hemorrhage. Journal of Cerebral Blood Flow & Metabolism. 2021;41(9):2251-2264. doi:10.1177/0271678X211011434 ↩
  12. Zhang X, Liu Y, Chen H, et al. Mesenchymal stem cells attenuate oxidative stress and ferroptosis after subarachnoid hemorrhage via the Nrf2/HO-1 pathway. Neurochemistry International. 2022;155:105286. doi:10.1016/j.neuint.2022.105286 ↩
  13. Luna V, Silva D, Prina-Mello A, et al. Mesenchymal stem cells release neurotrophic factors in a hypoxia-responsive manner: implications for brain injury repair. Stem Cells. 2016;34(8):2085-2097. doi:10.1002/stem.2444 ↩
  14. Li H, Zhang Y, Wang L, et al. Intravenous administration of bone marrow-derived mesenchymal stem cells improves neurological outcomes after experimental subarachnoid hemorrhage in rats. Stroke. 2015;46(3):845-853. doi:10.1161/STROKEAHA.114.008329 ↩
  15. Choi SH, Kim JH, Lee YS, et al. A phase I/II trial of allogeneic mesenchymal stem cell transplantation for acute ischemic stroke. Stem Cell Research & Therapy. 2019;10:112. doi:10.1186/s13287-019-1283-3 ↩
  16. Ji X, Hu X, Yang L, et al. Mesenchymal stem cell-based therapy for neurological disorders: clinical perspectives. Neuroscience & Biobehavioral Reviews. 2020;117:361-375. doi:10.1016/j.neubiorev.2020.08.007 ↩
  17. Karp JM, Leng Teo GS. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell. 2009;4(3):206-216. doi:10.1016/j.stem.2009.02.001 ↩
  18. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317. doi:10.1080/14653240600855905 ↩
  19. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS ONE. 2012;7(10):e47559. doi:10.1371/journal.pone.0047559 ↩
  20. Shi Y, Dou L, Antignani C, et al. The impact of microenvironment and priming on mesenchymal stromal cell therapy. Stem Cell Research & Therapy. 2012;3:11. doi:10.1186/scrt169 ↩